AIP
NBSE

Ameritas Investment Partners’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Ameritas Investment Partners’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-76
Closed -$11K – 3268
2021
Q1 		$11K Hold
76
– – ﹤0.01% 2828
2020
Q4 		$11K Hold
76
– – ﹤0.01% 2760
2020
Q3 		$12K Hold
76
– – ﹤0.01% 2651
2020
Q2 		$13K Buy
+76
New +$12.7K ﹤0.01% 2596

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's NBSE Position: Q2 2021 in Review

Ameritas Investment Partners sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 76 shares — an estimated $11K sold.

Ameritas Investment Partners first reported a position in NBSE in Q2 2020 and held it in 4 quarters. The position peaked at $13K in Q2 2020. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

  • Ameritas Investment Partners reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 76 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $11K.
  • Ameritas Investment Partners first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Ameritas Investment Partners's NeuBase Therapeutics, Inc. Common Stock position peaked at $13K in Q2 2020.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.